AQW051 + AQW051 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dyskinesias
Conditions
Dyskinesias, Drug-induced
Trial Timeline
Sep 15, 2011 → Feb 21, 2013
NCT ID
NCT01474421About AQW051 + AQW051 + Placebo
AQW051 + AQW051 + Placebo is a phase 2 stage product being developed by Novartis for Dyskinesias. The current trial status is completed. This product is registered under clinical trial identifier NCT01474421. Target conditions include Dyskinesias, Drug-induced.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01474421 | Phase 2 | Completed |
Competing Products
4 competing products in Dyskinesias
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Levodopa-carbidopa intestinal gel | AbbVie | Phase 3 | 77 |
| AFQ056 | Novartis | Phase 2 | 52 |
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |